Liz Shea | Vice President of Investor Relations |
Rick Gonzalez | Chairman of the Board & Chief Executive Officer |
Rob Michael | President & Chief Operating Officer |
Jeff Stewart | Executive Vice President & Chief Commercial Officer |
Carrie Strom | Senior Vice President, AbbVie and President, Global Allergan Aesthetics |
Tom Hudson | Senior Vice President, R&D & Chief Scientific Officer |
Scott Reents | Executive Vice President & Chief Financer |
Roopal Thakkar | Senior Vice President, Development & Regulatory Affairs & Chief Medical Officer |
Vamil Divan | Guggenheim Securities |
Chris Schott | JPMorgan |
Mohit Bansal | Wells Fargo |
Terence Flynn | Morgan Stanley |
Evan Seigerman | BMO |
Chris Raymond | Piper Sandler |
Steve Scala | TD Cowen |
Carter Gould | Barclays |
David Risinger | Leerink Partners |
Tim Anderson | Wolfe Research |
Geoff Meacham | Bank of America |
Good morning and thanks for joining us. Also on the call with me today are Rick Gonzalez, Chairman of the Board and Chief Executive Officer; Rob Michael, President and Chief Operating Officer; Jeff Stewart, Executive Vice President and Chief Commercial Officer; Scott Reents, Executive Vice President and Chief Financer; Carrie Strom, Senior Vice President, AbbVie and President, Global Allergan aesthetics; and Tom Hudson, Senior Vice President, R&D and Chief Scientific Officer.
Joining us for the Q&A portion of the call is Roopal Thakkar, Senior Vice President, Development and Regulatory Affairs and Chief Medical Officer.
Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements.